- Indication: Polymyalgia Rheumatica
- Enrollment Status: Enrollment Closed
- Protocol: CAIN457C22301+Extension
- Drug: COSENTYX® (secukinumab)
- Sponsor: Novartis
- Description: Novartis Pharmaceutical Trial entitled: A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR) Protocol No.: CAIN457C22301
